# US 2019/0314376 A1 · Fatty acid synthase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314376 A1
- Document ID: US20190314376A1
- Status: Published application
- Kind: A1
- Application number: 16/094,872
- Filed: 2017-04-20
- Published: 2019-10-17
- Earliest claimed: 2016-04-21
- Assignees: Duke University; Ohio State Innovation Foundation
- Applicants: Duke University; Ohio State Innovation Foundation
- Inventors: Jesse Kwiek; Timothy Haystaad; Philip Hughes; Yazan Aiwarawrah
- Web page: https://patentgrep.com/patent/US20190314376A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 33/243: Platinum; Compounds thereof
- A61P 31/18: for HIV
- C07D 495/04: Ortho-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to a method for inhibiting Fatty Acid Synthase (FASN) with a FASN inhibitor, methods for treating cancer and viral infections with a FASN inhibitor, and compounds and compositions inhibiting FASN.

## Claims

### Claim 1

A method of inhibiting Fatty Acid Synthase (FASN) with a FASN inhibitor that binds to the FASN purine-binding cofactor domain, the method comprising contacting cells that express FASN with an inhibitor that binds to the FASN purine-binding cofactor domain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inhibitor does not bind to the substrate domain.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibitor inhibits both acetate and glucose incorporation into total lipids.

### Claim 4 (depends on 3)

The method of claim 3, wherein the inhibitor inhibits both acetate and glucose incorporation into lipids in the HepG2 cell line with an IC50 value below about 300 nM.

### Claim 5 (depends on 1)

The method of claim 1, wherein the inhibitor possesses a thiophenopyrimidine scaffold.

### Claim 6 (depends on 1)

The method of claim 1, wherein the inhibitor possesses a thieno[2,3-d]pyrimidine scaffold.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound is (N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

### Claim 8

A method of promoting apoptosis in a cancer cell dependent on FASN activity, the method comprising contacting the cells with an inhibitor that binds to the FASN purine-binding cofactor domain.

### Claim 9 (depends on 8)

The method of claim 8, wherein the inhibitor does not bind to the substrate domain.

### Claim 10 (depends on 8)

The method of claim 8, wherein the inhibitor possesses a thiophenopyrimidine scaffold.

### Claim 11 (depends on 8)

The method of claim 8, wherein the inhibitor possesses a thieno[2,3-d]pyrimidine scaffold.

### Claim 12 (depends on 8)

The method of claim 8, wherein the compound is (N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

### Claim 13

A method of treating cancer in a subject, the method comprising administering to the subject in need thereof, a therapeutically effective amount of a FASN inhibitor that binds to the FASN purine-binding cofactor domain.

### Claim 14 (depends on 13)

The method of claim 13, wherein the inhibitor does not bind to the substrate domain

### Claim 15 (depends on 13)

The method of claim 13, wherein the cancer is selected from the group consisting of HER2-positive breast cancer, triple negative breast cancer, melanoma, hepatocellular carcinoma, and leukemia.

### Claim 16 (depends on 13)

The method of claim 13, wherein the inhibitor possesses a thiophenopyrimidine scaffold.

### Claim 17 (depends on 13)

The method of claim 13, wherein the inhibitor possesses a thieno[2,3-d]pyrimidine scaffold.

### Claim 18 (depends on 13)

The method of claim 13, wherein the compound is (N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 13)

The method of claim 13, wherein the inhibitor is co-administered with a platinum-based antineoplastic compound.

### Claim 20 (depends on 19)

The method of claim 19, wherein the inhibitor is co-administered with carboplatin or cisplatin.

### Claim 21 (depends on 19)

The method of claim 19, wherein the inhibitor is co-administered with carboplatin.

### Claim 22 (depends on 19)

The method of claim 19, wherein the dosage of platinum-based antineoplastic compound is less than that required when administered in the absence of a FASN inhibitor.

### Claim 23

A method of inhibiting viral replication in cells dependent on FASN expression, the method comprising contacting the cells with an inhibitor that binds to the FASN purine-binding cofactor domain.

### Claim 24 (depends on 23)

The method of claim 23, wherein the inhibitor does not bind to the substrate domain

### Claim 25 (depends on 23)

The method of claim 23, wherein the inhibitor inhibits HIV viral replication in a TZM-bl model of HIV replication with an EC50 value below about 500 nM.

### Claim 26 (depends on 23)

The method of claim 23, wherein inhibition of FASN reduces HIV-1 particle production without affecting intracellular Gag production.

### Claim 27 (depends on 23)

The method of claim 23, wherein the inhibitor attenuates HIV replication during a late stage of its replication cycle.

### Claim 28 (depends on 23)

The method of claim 23, wherein nascent HIV-1 virion production is inhibited without reducing HIV-1 protein synthesis.

### Claim 29 (depends on 23)

The method of claim 23, wherein the inhibitor possesses a thiophenopyrimidine scaffold.

### Claim 30 (depends on 23)

The method of claim 23, wherein the inhibitor possesses a thieno[2,3-d]pyrimidine scaffold.

### Claim 31 (depends on 23)

The method of claim 23, wherein the compound is (N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

### Claim 32

A method of treating a viral infection in a subject, the method comprising administering to the subject in need thereof, a therapeutically effective amount of a FASN inhibitor that binds to the FASN purine-binding cofactor domain.

### Claim 33 (depends on 32)

The method of claim 32, wherein the viral load is reduced.

### Claim 34 (depends on 32)

The method of claim 32, wherein the viral infection is infection by an enveloped virus.

### Claim 35 (depends on 32)

The method of claim 32, wherein the viral infection is infection by a virus selected from the group consisting of human immunodeficiency virus, cytomegalovirus, Dengue, hepatitis B, hepatitis C, Epstein-Barr, influenza virus, respiratory syncytial virus and West Nile virus.

### Claim 36 (depends on 32)

The method of claim 32, wherein the virus is human immunodeficiency virus.

### Claim 37 (depends on 32)

The method of claim 32, wherein lipid dysregulation-based morbidities are reduced.

### Claim 38 (depends on 32)

The method of claim 32, wherein the inhibitor possesses a thiophenopyrimidine scaffold.

### Claim 39 (depends on 32)

The method of claim 32, wherein the inhibitor possesses a thieno[2,3-d]pyrimidine scaffold.

### Claim 40 (depends on 32)

The method of claim 32, wherein the compound is (N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof.

### Claim 41 (depends on 32)

The method of claim 32, further comprising co-administration of an additional anti-retroviral compound.

### Claim 42

A pharmaceutical composition comprising (N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 43

The compound (R)—(N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine or a pharmaceutically acceptable salt thereof.

### Claim 44

The compound (S)—(N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine or a pharmaceutically acceptable salt thereof.
